MIR150 (MicroRNA 150)

Several EMT-related miRNAs show consistent associations with invasion, metastasis, peritoneal dissemination, prognosis, and chemoresistance, and many are detectable in circulation. Overall, EMT-related miRNAs orchestrate gastric cancer cell plasticity and tumor-microenvironment crosstalk and represent promising biomarker and therapeutic candidates that warrant validation in prospective, subtype-stratified, and translational studies.

In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.

[This retracts the article DOI: 10.3892/ol.2016.5046.].

Ingenuity Pathway Analysis (IPA) revealed that miR-16-5p and other miRNAs with seed AGCAGCA formed the largest interaction network in GBM, while disease enrichment analysis using Database for Annotation, Visualization, and Integrated Discovery (DAVID) confirmed that the 1000 predicted mRNA targets of DE-miRNAs in GBM were disease relevant. Collectively, these findings identify a robust panel of CSF-derived miRNAs capable of distinguishing IDH-mutant gliomas, GBM, and non-tumor states, supporting the potential of EV-miRNAs as minimally invasive biomarkers for the molecular characterization of diffuse gliomas.

An integrative pipeline identifies a four-miRNA signature associated with lung metastasis and delivers a translational PFI nomogram. Concordant experimental data and serum biomarkers reinforce biological plausibility and clinical potential, including liquid-biopsy applications.

Circulating miRNA profiling showed upregulation of inflammation-associated miRNAs (miR-21-5p, miR-150-5p, miR-142-3p, miR-363-3p), linked through bioinformatic analysis to immune dysregulation, intestinal cancer, and neurotoxicity. Overall, these results indicate that low-dose exposure to pollutant mixtures can induce subtle but biologically relevant immune and epithelial changes, emphasizing the importance of mixture-based approaches in environmental risk assessment.

Mechanistically, miR-182-5p enhanced metastasis via ANLN and PDE4D regulation, whereas miR-203, miR-150-5p, and miR-139-5p suppressed metastasis through PDE4D, NEGR1, and ATP11A pathways, respectively. These results highlight the opposing roles of miR-182-5p and the tumor-suppressive miRNAs in CRC metastasis and suggest their potential as biomarkers and therapeutic targets.

A rescue experiment revealed that NR4A1 knockdown partially reversed the Antagomir-150-induced up-regulation of P4 synthesis and apoptosis. Overall, this study demonstrates that miR-150 contributes to P4 synthesis and apoptosis in goat luteal cells by targeting NR4A1.

Clinically, plasma ZFAS1 demonstrates enhanced diagnostic utility when combined with alpha-fetoprotein (AUC = 0.891), while therapeutic targeting of ZFAS1-mediated PI3K-AKT and PERK/ATF4 pathways shows promise in overcoming sorafenib/donafenib resistance. Current translational challenges include ZFAS1 isoform heterogeneity, suboptimal liquid biopsy sensitivity, and dynamic TME interactions. Future directions should employ multi-omics integration (spatial transcriptomics/single-cell sequencing) coupled with AI-driven network modeling to systematically decode ZFAS1's regulatory architecture, ultimately enabling precision theranostic strategies for HCC management.

These findings suggest that hsa-miR-150-5p is a key regulator in HCV-associated liver disease, with upregulation observed in both HCV and HIV-HCV coinfection groups, potentially influencing transcriptional and network-level regulation. This systems-level framework highlights miR-150-5p as a potential biomarker for HCV and HIV-HCV associated liver pathology, providing a basis for future studies toward precision interventions in viral coinfection-mediated oncogenesis.

Therapeutically, tailored strategies employing miR-150 mimics, antagomiRs, or ceRNA-targeted inhibitors hold potential for disrupting metastatic pathways; however, challenges such as isoform-specific targeting, precise delivery, and mitigation of off-target effects remain unresolved. In our view, framing miR-150 as a "double-edged sword" in metastatic regulation provides a conceptual framework for leveraging its molecular versatility to advance precision oncology and mitigate metastatic progression, particularly in combination with emerging systemic therapies.

MiR-126-5p, miR-150-5p, miR-214-3p, and miR-452-5p all showed a decrease in expression at at least one timepoint following splenectomy. These miRNAs have been previously shown to have roles in angiogenesis and pathways known to be involved in the pathogenesis of hemangiosarcoma and may be prospective targets for a minimally invasive diagnostic panel for the presence of splenic hemangiosarcoma.